Neeland IJ, Eliasson B, Kasai T, et al. - In the EMPA-REG OUTCOME trial, researchers sought to investigate the effects of empagliflozin on the incidence of obstructive sleep apnea (OSA) and its impacts on metabolic, cardiovascular (CV), and renal outcomes among participants with or without OSA. In addition to standard of care, participants with diabetes and CV disease were randomized to empagliflozin (10 and 25 mg) or placebo daily. In 391 of 7,020 (5.6%) participants at baseline, OSA was reported. In EMPA-REG OUTCOME, OSA participants had greater comorbidity and higher CV and renal events frequency. Empagliflozin, independent of preexisting OSA, has had positive effects on risk factors and CV and renal outcomes and may also decrease the risk for new-onset OSA.